stockrowMatinas Biopharma Holdings, Inc.
MTNB Healthcare Biotechnology
Matinas Biopharma Holdings, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.1 million, down 65.6% from fiscal 2022.
- EPS
- +79.6%
- Free cash flow
- +9.15%
- Total debt
- −54.5%
Quarter to June 2026, against a year earlier
Follow MTNB
Alert me
Matinas Biopharma Holdings, Inc. (MTNB) EV/Sales
As of 6 November 2026, Matinas Biopharma Holdings, Inc. (MTNB) trades at a EV/Sales of −0.1×. Over the past ten years it has ranged from −9.2× (February 2016) to 1,595× (May 2017); the current reading is higher than 12% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 8.2× | (69.90%) |
| FY2022 | 27.2× | (96.79%) |
| FY2021 | 849× | 37.21% |
| FY2020 | 619× | (47.82%) |
| FY2019 | 1,186× | 440.59% |
| FY2018 | 219× | (68.67%) |
| FY2017 | 700× | — |
| FY2015 | −2.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2023 | 18.0× | (33.77%) |
| Dec 2022 | 27.2× | (45.84%) |
| Sep 2022 | 50.3× | (57.37%) |
| Jun 2022 | 118× | (86.11%) |
| 15 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ELAB PMGC Holdings Inc. compare | −6.9× |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR compare | −2.8× |
| MTNB Matinas Biopharma Holdings, Inc. | −0.1× |
| BBLG Bone Biologics Corp. compare | n/m |
| PTIX Atrinsic Inc. compare | n/m |
| ARTL Artelo Biosciences, Inc. compare | n/m |
| LABT Lakewood-Amedex Biotherapeutics Inc. compare | n/m |
| BPTH Bio-Path Holdings, Inc. compare | n/m |
| VBIO Valion Bio, Inc. compare | 11.1× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)